Key Takeaways:
-
AstraZeneca left after the asthma candidate was linked with lung events in a non-clinical trial.
Pieris Pharmaceuticals, Inc. will slash its workforce by 70% under a broader cost-saving plan in a bid to buy the firm more time to clinch partnerships or even a full exit deal after AstraZeneca PLC walked away from a partnership for a protein-based drug candidate for asthma.
Pieris and AstraZeneca teamed up on elarekibep in 2017 under a deal in which Pieris received $57.5m in upfront and...
Welcome to Scrip
Create an account to read this article
Already a subscriber?